Press Releases

AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonstrating significant reductions in the annual asthma exacerbation rate...

Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management. The findings from more than 1,700 rheumatologists* in 15 countries builds upon...

AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonstrating significant reductions in the annual asthma exacerbation rate...

Otsuka Holdings Co Ltd announced the signing of a development and commercialization agreement with ReCor Medical Inc. together with an additional investment. As part of the agreement, Otsuka Holdings.   obtained exclusive rights to the commercialization...

Visionary, up to $2 billion multi-year alliance to focus on development of new gene therapy and gene editing technologies and create a therapeutic platform for a broad range of diseases Biogen to team up with renowned gene therapy...

Chugai Pharmaceutical Co Ltd. announced that it obtained a supplemental approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 13, 2016, for “CellCept®. Capsules 250” and “CellCept® Powder for Oral Suspension 31.8%”...

Chugai Pharmaceutical Co Ltd announced that its co-sponsorship of “Relay for Life Japan” (Organizer: Japan Cancer Society etc.), a charity activity aiming to support cancer patients and their families, and encourage the entire community to confront and conquer cancer...